http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 08 Sep 2026 07:00:21 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Novartis+starts+Phase+2+trial+for+Monte+Rosa+drug%2C+triggering+%2450M+payment/27032969.html <p>Monte Rosa Therapeutics (Nasdaq: GLUE) announced that Novartis has initiated a Phase 2 clinical study for MRT-6160 (DDY391), a VAV1-directed molecular glue degrader, in participants with Sjögren's disease. The milestone triggers a $50 million payment to Monte Rosa from Novartis.</p> <p>The study is a Phase 2a/b, randomized, double-blind, placebo-controlled, multi-center trial evaluating the efficacy, safety, and tolerability of up to 52 weeks of treatment with MRT-6160 (DDY391). The trial is listed on ClinicalTrials.gov under identifier NCT07737743.</p> <p>Novartis holds exclusive worldwide rights to develop, manufacture, and commercialize MRT-6160 and other VAV1 molecular glue degraders under a global exclusive license agreement with Monte Rosa. http://www.streetinsider.com/FDA/Novartis+starts+Phase+2+trial+for+Monte+Rosa+drug%2C+triggering+%2450M+payment/27032969.html Tue, 08 Sep 2026 07:00:21 -0400 GLUE http://www.streetinsider.com/Press+Releases/Monte+Rosa+Therapeutics+Announces+Milestone+Achievement+Associated+with+Initiation+of+Phase+2+Clinical+Study+for+VAV1-directed+Molecular+Glue+Degrader+MRT-6160+%28DDY391%29/27032918.html <p align="center"><em>Phase 2 study to be conducted in participants with Sjögren’s disease</em></p> <p align="center"><em>Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa</em></p> <p align="center"><em>Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study </em></p> <p align="center"><em>Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones </em></p> <p>BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=DfJdq1TBW0X9olI7nl1pGafVZq2tRFRjT7Cv-wH6kO71PbhEwqtCAnaXM-tAxHR46tfnjPFT_KVKsrPTmC8nH1AgU4P_Y6U1IKsokbhOkFaMGU7RgBZpdGtGoEPXHJnZ" rel="nofollow" target="_blank"><u>Monte Rosa Therapeutics, Inc.</u></a> (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader http://www.streetinsider.com/Press+Releases/Monte+Rosa+Therapeutics+Announces+Milestone+Achievement+Associated+with+Initiation+of+Phase+2+Clinical+Study+for+VAV1-directed+Molecular+Glue+Degrader+MRT-6160+%28DDY391%29/27032918.html Tue, 08 Sep 2026 07:00:00 -0400 GLUE http://www.streetinsider.com/Globe+Newswire/Monte+Rosa+Therapeutics+Announces+Milestone+Achievement+Associated+with+Initiation+of+Phase+2+Clinical+Study+for+VAV1-directed+Molecular+Glue+Degrader+MRT-6160+%28DDY391%29/27032918.html <p align="center"><em>Phase 2 study to be conducted in participants with Sjögren’s disease</em></p> <p align="center"><em>Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa</em></p> <p align="center"><em>Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study </em></p> <p align="center"><em>Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones </em></p> <p>BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=DfJdq1TBW0X9olI7nl1pGafVZq2tRFRjT7Cv-wH6kO71PbhEwqtCAnaXM-tAxHR46tfnjPFT_KVKsrPTmC8nH1AgU4P_Y6U1IKsokbhOkFaMGU7RgBZpdGtGoEPXHJnZ" rel="nofollow" target="_blank"><u>Monte Rosa Therapeutics, Inc.</u></a> (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader http://www.streetinsider.com/Globe+Newswire/Monte+Rosa+Therapeutics+Announces+Milestone+Achievement+Associated+with+Initiation+of+Phase+2+Clinical+Study+for+VAV1-directed+Molecular+Glue+Degrader+MRT-6160+%28DDY391%29/27032918.html Tue, 08 Sep 2026 07:00:00 -0400 GLUE http://www.streetinsider.com/Press+Releases/Monte+Rosa+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27018763.html <p>BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- <strong>Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), </strong>a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to six newly hired non-executive employees as a material inducement to commencing their employment with the Company.</p> <p>The employees received, in the aggregate, non-qualified stock options to purchase 31,145 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $14.31 as reported by Nasdaq on September 1, the effective date of the grant http://www.streetinsider.com/Press+Releases/Monte+Rosa+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27018763.html Wed, 02 Sep 2026 16:01:00 -0400 GLUE http://www.streetinsider.com/Globe+Newswire/Monte+Rosa+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27018763.html <p>BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- <strong>Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), </strong>a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to six newly hired non-executive employees as a material inducement to commencing their employment with the Company.</p> <p>The employees received, in the aggregate, non-qualified stock options to purchase 31,145 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $14.31 as reported by Nasdaq on September 1, the effective date of the grant http://www.streetinsider.com/Globe+Newswire/Monte+Rosa+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27018763.html Wed, 02 Sep 2026 16:01:00 -0400 GLUE http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Press+Releases/Monte+Rosa+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/27008569.html <p align="left">BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=pE6gpejvZc3FEuZ8VGZ7u41qcRJma8Wzq1fU1MqaHqT6X5H4EnzzLTDZm51oYuP0Y6QOLxviavNb-hgH_7QePMZMXAnMPeQDzus5rD5YLjLVZ-MIKqsyjj8cCHi7QG0G" rel="nofollow" target="_blank"><u>Monte Rosa Therapeutics, Inc.</u></a> (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:</p> <ul type="disc"><li>Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 10, 2026, at 12:45 p.m. ET</li><li>Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY) – September 14, 2026<br /><br /></li></ul> <p>A webcast of the fireside chat will be accessible via the “Events &amp; http://www.streetinsider.com/Press+Releases/Monte+Rosa+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/27008569.html Tue, 01 Sep 2026 07:00:00 -0400 GLUE http://www.streetinsider.com/Globe+Newswire/Monte+Rosa+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/27008569.html <p align="left">BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=pE6gpejvZc3FEuZ8VGZ7u41qcRJma8Wzq1fU1MqaHqT6X5H4EnzzLTDZm51oYuP0Y6QOLxviavNb-hgH_7QePMZMXAnMPeQDzus5rD5YLjLVZ-MIKqsyjj8cCHi7QG0G" rel="nofollow" target="_blank"><u>Monte Rosa Therapeutics, Inc.</u></a> (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:</p> <ul type="disc"><li>Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 10, 2026, at 12:45 p.m. ET</li><li>Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY) – September 14, 2026<br /><br /></li></ul> <p>A webcast of the fireside chat will be accessible via the “Events &amp; http://www.streetinsider.com/Globe+Newswire/Monte+Rosa+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/27008569.html Tue, 01 Sep 2026 07:00:00 -0400 GLUE http://www.streetinsider.com/FDA/Monte+Rosa+doses+first+patient+in+phase+2+prostate+cancer+study/26964035.html <p>Monte Rosa Therapeutics (Nasdaq: GLUE) announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 clinical trial evaluating MRT-2359 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor (AR) mutations.</p> <p>The study, identified as NCT07745361 on clinicaltrials.gov, will enroll up to 25 patients using a Simon's two-stage design. MRT-2359 will be administered orally at 0.5 mg on a 21 days on, 7 days off schedule over 28-day cycles, combined with apalutamide, a second-generation AR inhibitor. Eligible patients must have confirmed AR mutations and prior treatment with a second-generation AR inhibitor.</p> <p>Study endpoints include http://www.streetinsider.com/FDA/Monte+Rosa+doses+first+patient+in+phase+2+prostate+cancer+study/26964035.html Mon, 24 Aug 2026 07:00:17 -0400 GLUE http://www.streetinsider.com/Press+Releases/Monte+Rosa+Therapeutics+Announces+First+Patient+Dosed+in+MODeFIRe-1%2C+a+Phase+2+Study+of+MRT-2359+in+Combination+with+Apalutamide+in+Patients+with+AR+Mutation-Positive+Metastatic+Castration-Resistant+P/26963995.html <p align="center"><em>Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety</em></p> <p align="center"><em>Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with advanced CRPC expected by end of year </em></p> <p>BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first patient has been dosed in MODeFIRe-1 (clinicaltrials.gov identifier NCT07745361), a Phase 2 study evaluating MRT-2359 in combination with apalutamide, a second-generation androgen receptor (AR) inhibitor, in http://www.streetinsider.com/Press+Releases/Monte+Rosa+Therapeutics+Announces+First+Patient+Dosed+in+MODeFIRe-1%2C+a+Phase+2+Study+of+MRT-2359+in+Combination+with+Apalutamide+in+Patients+with+AR+Mutation-Positive+Metastatic+Castration-Resistant+P/26963995.html Mon, 24 Aug 2026 07:00:00 -0400 GLUE http://www.streetinsider.com/Globe+Newswire/Monte+Rosa+Therapeutics+Announces+First+Patient+Dosed+in+MODeFIRe-1%2C+a+Phase+2+Study+of+MRT-2359+in+Combination+with+Apalutamide+in+Patients+with+AR+Mutation-Positive+Metastatic+Castration-Resistant+P/26963995.html <p align="center"><em>Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety</em></p> <p align="center"><em>Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with advanced CRPC expected by end of year </em></p> <p>BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first patient has been dosed in MODeFIRe-1 (clinicaltrials.gov identifier NCT07745361), a Phase 2 study evaluating MRT-2359 in combination with apalutamide, a second-generation androgen receptor (AR) inhibitor, in http://www.streetinsider.com/Globe+Newswire/Monte+Rosa+Therapeutics+Announces+First+Patient+Dosed+in+MODeFIRe-1%2C+a+Phase+2+Study+of+MRT-2359+in+Combination+with+Apalutamide+in+Patients+with+AR+Mutation-Positive+Metastatic+Castration-Resistant+P/26963995.html Mon, 24 Aug 2026 07:00:00 -0400 GLUE http://www.streetinsider.com/New+Coverage/TD+Cowen+Assumes+Monte+Rosa+Therapeutics+%28GLUE%29+at+Buy/26962944.html <p>TD Cowen analyst Tyler Van Buren assumes coverage on Monte Rosa Therapeutics (NASDAQ: GLUE) with a Buy rating.</p> <p>For an analyst ratings summary and ratings history on Monte Rosa Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=GLUE">click here</a>. For more ratings news on Monte Rosa Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=GLUE&amp;type=analyst">click here</a>.</p> <p>Shares of Monte Rosa Therapeutics closed at $14.30 yesterday.</p> http://www.streetinsider.com/New+Coverage/TD+Cowen+Assumes+Monte+Rosa+Therapeutics+%28GLUE%29+at+Buy/26962944.html Sat, 22 Aug 2026 07:54:31 -0400 GLUE